Page 5 - 《中国药房》2022年15期

CHINA PHARMACY

Volume 33，Number 15，August 15，2022

Semimonthly
Table of Contents

Expert consensus on the comprehensive clinical evaluation of lipid-lowering drugs under the centralized drug
volume-based procurement policy in Shandong Province …………………………………………………………
…………………………………………… Pharmacoeconomics Committee of Shandong Hospital Association（1793）
Study on the mechanism，specific path and code of conduct of pharmaceutical enterprises’participation in American
active surveillance system and its enlightenment …………………………………………………………………
………………………………………………… GE Siyi，CHEN Wei，WU Mingyang，XU Yiming，LIANG Yi（1799）
Analysis on the expression of drug standards and related issues in the newly revised Drug Administration Law
…… NIE Heyun，SONG Minxian，YAN Guiping，XIE Ming，GUAN Yongmei，YAN Dongmei，ZHU Weifeng（1806）
Correlation analysis between the judgment of medical damage liability disputes related to off-label drug use and
evidence-based evidence ………………………………………………………………………………… BAO Qi，
HU Lin，HU Huajie，HUANG Tao，FU Mengyuan，Haishaerjiang·Wushouer，GUAN Xiaodong，SHI Luwen（1810）
Evaluation of efficiency of drug safety supervision in China based on DEA model and Malmquist index ………

……………………………………………………………………………… DUAN Xiaoxiang，WANG Shuling（1814）
Study on the mechanism of Wenyang huazhuo tongluo formula contained serum inhibiting the proliferation of

Th17 cells in scleroderma patients …………………………………………………………………………………
……………………………… GUO Kelei，LI Yingli，BIAN Bo，HAN Li，LI Kai，ZHANG Hong，BIAN Hua（1820）
Study on the effects of Qingjie huagong decoction on the regulation of intestinal flora and intestinal mucosal
barrier in severe acute pancreatitis model rats …………………………………… QIN Baijun，TANG Xiping，
YANG Xin，YANG Lei，FENG Minchao，ZHANG Chi，HONG Xiaohua，LAN Yanmei，CHEN Guozhong（1825）
Evaluation of the quality of different germplasms of Rehmannia glutinosa based on iridoid glycosides …………
………………………………………… GENG Xiaotong，XIE Caixia，ZHANG Nan，LI Jinping，CHEN Qiong（1833）
Content determination of five constituents in Shenfukang Ⅱ capsule by HPLC …………………………………
…… YIN Jiyao，SHEN Xia，HU Jing，CUI Xiaomin，REN Hui，QU Tong，LI Ning，QU Kai，CHEN Zhiyong（1838）
Analysis of the development trend of small nucleic acid drugs ……………………………………………………
……………………………………………………… QIAO Zhiwei，YOU Jin，ZOU Yue，LI Yang，LI Hongyu（1842）
Intervention effects of Jinkui shenqi pills on renal fibrosis model rats and its mechanism ………………………
…………………… ZHANG Minghao，ZU Zhaoxuan，ZHANG Tong，GUO Shen，DU Jingwen，ZHAO Shen（1848）
Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced or recurrent
non-small cell lung cancer …………… GAO Hongting，HU Mengxue，JIA Linlin，WU Fang，HOU Yanhong（1854）
Cost-utility analysis of durvalumab for consolidation therapy after chemoradiotherapy for stage Ⅲ non-small cell
lung cancer …………………… SHI Jian，QI Ran，GAO Shengnan，LIU Xuting，DU Guiping，LIU Guoqiang（1860）
Adverse drug event signal mining of semaglutide based on FDA Adverse Event Reporting System database ……
…………………………………………………………………………… LU Weitao，HE Jiaru，CHEN Wenying（1865）
Clinical comprehensive evaluation for Chinese patent medicine based on evidence-based medicine and pharma-
coeconomic model ………… TANG Xianshuai，ZHENG Lei，ZHANG Mingzhu，GUAN Yuyao，YANG Jing（1870）
Analysis on research hotspots and frontier in domestic evidence-based traditional Chinese medicine ……………
…………………………………………… RONG Hongguo，YU Weijie，DU Meijiao，DONG Yue，FEI Yutong（1876）
Visual analysis of research progress of pharmacy intravenous admixture service in China based on bibliometrics
……………………………………………… LI Qiuyue，LI Zhashi，ZHAO Huaibi，SONG Qilian，LI Guochun（1881）